Introduction
============

Acid/base homeostasis is vital for life because protein and enzyme functions, cell structures and membrane permeability are altered by changing pH. In most epithelia, transepithelial chloride absorption and bicarbonate secretion are associated with fluid secretion, which is important for normal functioning. Slc26 anion exchangers are members of a recently discovered gene family with multifunctional transmembrane proteins. These proteins mediate the transport of various monovalent and divalent anions, including chloride, bicarbonate, sulfate, iodide and oxalate, mainly across the plasma membrane of epithelial cells and contribute to the composition and pH of secreted fluids in the body ([@B18]). This gene family consists of 11 members and is divided into three groups, e.g., selective sulfate transporters, Cl^-^/HCO~3~^-^ exchangers and anion channels, based on their proven or putative transport properties ([@B34]; [@B17]; [@B35]; [@B1]). Slc26a9 is classified into the third group and expressed in the apical membrane of multiple organs to regulate Cl^-^ and HCO~3~^-^ transport by different ion transport methods. In this review, we discuss the current knowledge of the expression pattern, functional diversity, regulatory mechanism and pathophysiology of this novel protein in different organs.

Cloning, Expression and Physiological Functions of Slc26a9 in Different Organs
------------------------------------------------------------------------------

Slc26a9 (solute carrier family 26 member 9) is a member of the Slc26 family of multifunctional anion transporters. Slc26a9 was cloned on the basis of its homology to other Slc26 isoforms. In humans, SLC26A9 maps to chromosome 1 and encodes a 791-amino-acid protein ([@B28]). SLC26A9 (human)/Slc26a9 (mouse) is expressed at high levels in the lung ([@B28]) and stomach ([@B53]; [@B26]), to some extent in the proximal duodenum, and at low levels in the distal duodenum and pancreas ([@B26]). Slc26a9 is also detected in some specialized cells in the kidney ([@B2]), neural system ([@B12]), reproductive tract ([@B16]), salivary gland ([@B50]), and prostate ([@B28]). Although Slc26a9 is not expressed in normal enamel cells ([@B22]), it is upregulated in Slc26a1 and Slc26a7 null mice, suggesting that it plays a strong compensatory role during enamel maturation ([@B54]). Functional studies showed that Slc26a9 is involved in diverse transport modes in different systems. First, recent work in *Xenopus* oocytes, Fischer rat thyroid epithelial cells, HEK cells and COS-7 cells expressing Slc26a9 has shown that Slc26a9 is a highly selective Cl^-^ channel with minimal OH/HCO~3~ permeability that is regulated by with-no-lysine kinases (WNK) and cystic fibrosis transmembrane conductance regulator (CFTR) in heterologous cells ([@B16]; [@B29]; [@B9]; [@B43]). Loriol et al. reported that the conductivity of Slc26a9 is enhanced at high HCO~3~^-^ concentrations ([@B29]). Second, electrophysiological experiments involving *Xenopus* oocytes, HEK cells, and animal models have attributed the following three different transport modes to Slc26a9: Cl^-^ channel ([@B29]; [@B9]; [@B5]; [@B36]; [@B2]), Cl^-^/HCO~3~^-^ exchanger ([@B52]; [@B15]) and Na^+^ transporter ([@B12]). Additionally, the Slc26a9 protein plays multiple physiological roles in the transport of several anions, including I^-^, NO3, gluconate, SO~4~^2-^, and Br^-^, at different conductances ([@B16]; [@B29]).

Slc26a9 Functions as a Cl^-^ Channel in the Airway
--------------------------------------------------

Slc26a9 is predominantly expressed in the apical membrane of alveolar, tracheal, and bronchiolar epithelial cells in the lung ([@B28]; [@B9]; [@B27]). Initial studies have shown that Slc26a9 contributes to constitutive and cyclic adenosine monophosphate (cAMP)-dependent Cl^-^ secretion in cultured human bronchial epithelial (HBE) cells, and Slc26a9 has been suggested to functionally interact with CFTR *in vitro* ([@B9]; [@B5]), indicating that Slc26a9 may serve as a chloride channel that compensates for CFTR dysfunction in CF. Based on the functional properties of Slc26a9 in transduced cells and its expression pattern in human and mouse airways ([@B28]; [@B12]), questions regarding the function of Slc26a9 in maintaining airway surface liquid (ASL) homeostasis in health and allergic airway disease have emerged. Studies investigating the function of Slc26a9 in native epithelia have been performed in the lung of Slc26a9 null mice, and the essential role of Slc26a9 in mediating Cl^-^ secretion and preventing mucus obstruction during airway inflammation induced by IL-13 instillation ([@B4]), but not under physiological conditions, has been identified. This finding suggests that anion conductance, which was found to be upregulated in allergic airway inflammation in a previous study ([@B3]), may indeed occur through Slc26a9 and that the inability to activate this conductance may result in an increase in airway pathology. Taken together, these data indicate that besides TMEM16A and CFTR, Slc26a9 functions as an alternative chloride channel that may contribute to the regulation of ASL, which is essential for mucus clearance under pathophysiological conditions in the airways.

Slc26a9 Is Involved in Various Ion Transport Systems in the Digestive System
----------------------------------------------------------------------------

### In the Stomach

Slc26a9 is highly expressed in the apical membrane of parietal cells, surface epithelial cells and deep cells in the gastric glands and is co-localized with H^+^/K^+^-ATPase expression ([@B52], [@B53]). The initial characterization of Slc26a9 transport by the measurements of intracellular pH (pH~i~) suggested that Slc26a9 can function as a Cl/HCO~3~ exchanger in gastric surface cells to support HCO~3~^-^ secretion in the stomach, which can be inhibited by NH4^+^ *in vivo* ([@B52]). These results raise the question of whether the expression of Slc26a9 is reduced during *Helicobacter pylori* (*H. pylori*, Hp) infection due to the production of ammonia (NH3)/NH~4~^+^ through its urease activity, which may predispose patients to acidic injury and peptic ulcers by impairing Slc26a9-mediated gastric HCO~3~^-^ secretion. However, a subsequent study showed that the mRNA and protein expression levels of Slc26a9 are not altered in gastric surface epithelial cells in Hp-infected mice, which might be a compensatory response to overcome the chronic inhibition of Slc26a9-mediated HCO~3~^-^ secretion by the Hp infection ([@B21]). Subsequently, Demitrack et al. demonstrated that Slc26a9 can activate cellular HCO~3~^-^ secretion through its anion transporter if the gastric epithelium is damaged ([@B15]). Collectively, these observations suggest that Slc26a9 functions as a Cl^-^/HCO~3~^-^ exchanger. However, based on a Slc26a9-deficient mouse model, functional experiments have shown that the deletion of Slc26a9 results in impaired acid secretion, indicating that Slc26a9 can function as a Cl^-^ channel ([@B53]). Moreover, the absence of Slc26a9 expression in the murine stomach at young age causes parietal cell loss, hypochlorhydria and massive fundic hyperplasia ([@B53]), suggesting that the Slc26a9 gene is essential for parietal cell function and survival. Loss of parietal cells is known to contribute to a premalignant environment in the gastric mucosa, and gastric cancer normally develops in the setting of parietal cell loss and mucous cell metaplasia ([@B20]). Thus, Slc26a9 deficiency may promote gastric carcinogenesis and should be intensively investigated.

### In the Duodenum

Recently, polymorphisms in the *slc26a9* gene were associated with an increased risk of meconium ileus (MI) in infants with cystic fibrosis (CF) ([@B49]), which addresses the question regarding the expression and function of Slc26a9 in the intestine. Early expression data showed that low levels of Slc26a9 were detected in the duodenum ([@B52]). However, a significant reduction in basal duodenal HCO~3~^-^ secretion was observed in Slc26a9-deficient duodenum *in vivo*, and forskolin-induced stimulation did not alter HCO~3~^-^ secretion. Additionally, both luminal low acid and prostaglandin E2 (PGE2) treatments strongly reduced HCO~3~^-^ secretion in the absence of Slc26a9 expression, suggesting that Slc26a9 plays an important role in orchestrating the acid-induced duodenal HCO~3~^-^ secretory response ([@B45]). Subsequently, a more precise study found that Slc26a9 was detected in the proximal duodenum but not in the more distal part of the intestine where MI occurs ([@B26]). The loss of Slc26a9 expression resulted in reduced survival of CFTR-deficient mice and strongly impaired HCO~3~^-^ and fluid secretion in the proximal duodenum, particularly at a young age, indicating that Slc26a9 plays a key role in regulating HCO~3~^-^ secretory and fluid absorptive changes in the proximal duodenal mucosa despite the low Slc26a9 expression at the whole organ level ([@B26]). The association between Slc26a9 and MI might be related to the absence or malfunction of Slc26a9 in the upper GI tract, which results in maldigestion and impaired downstream signaling. More importantly, we depict the following four potential ion transport modes of Slc26a9 in the duodenum: a. Slc26a9 is located in the crypts of the duodenum and functions as a chloride channel (similar to CFTR) to facilitate Cl^-^ recycling via another Cl^-^/HCO~3~^-^ exchanger, b. Slc26a9 functions as an anion exchanger that is functionally coupled to CFTR to regulate HCO~3~^-^ secretion, c. Slc26a9 and CFTR interact structurally and/or functionally in a positive fashion to enhance HCO~3~^-^ secretion, and d. Slc26a9 is a crypt enterocyte anion channel that functions indirectly in transepithelial anion transport but is possibly involved in volume control/apoptosis/migration/differentiation. In this case, the altered ion transport could be a secondary phenomenon based on the changes in cellular growth and differentiation patterns. Therefore, the importance of Slc26a9 in the regulation of HCO~3~^-^ secretion may offer a new possibility for the protection of duodenum ulcer, as HCO~3~^-^ secretion is essential for maintaining acid/base homeostasis and mucosal protection in the duodenum.

### In the Pancreas and Biliary System

Polymorphisms in Slc26a9 are associated with an increased incidence and poor prognosis of diabetic individuals with CF ([@B10]), However, knowledge of the expression and function of Slc26a9 in the pancreas and biliary system is lacking. We found that Slc26a9 was expressed in the pancreatic parenchyma, liver, gallbladder and microdissected pancreatic and bile ducts at low levels ([@B26]). Afterward, functional data showed that the deletion of Slc26a9 is associated with a reduction in pancreatic fluid, but not HCO~3~^-^ secretion, in young female mice. This finding demonstrates that Slc26a9 plays a role in pancreatic ductal physiology despite the fairly low expression levels compared to those of CFTR and other electrolyte transporters. Furthermore, a slight reduction in the normalization of blood glucose levels was observed after an intravenous glucose bolus in older female mice. The female preponderance for an Slc26a9-related loss of ductal function is interesting in the context of the higher incidence of diabetes in female CF patients ([@B24]). Thus, Slc26a9 can function as an alternative chloride channel to regulate fluid absorption and glucose metabolism in the pancreas, suggesting that Slc26a9 may not only be involved in CF-related diabetes (CFRD) onset but also may contribute to the occurrence of Type 2 diabetes.

### Role of Slc26a9 in the Kidney

Slc26a9 is mainly found in the medulla and cultured medullary collecting duct cells and is located on the apical membrane of a subset of cells in the outer medullary collecting duct (OMCD), the initial portion of the inner medullary collecting duct (IMCD), and principal cells ([@B2]; [@B47]). Functional analyses showed that the absence of Slc26a9 in mouse results in impaired chloride and sodium excretion after exposure to a high-salt diet or water deprivation. This impairment is accompanied by elevated systemic arterial pressure, suggesting that Slc26a9 functions as a Cl^-^ channel that regulates renal salt excretion and blood pressure ([@B2]). However, RT-PCR analyses and pHi measurements in cultured proximal tubular cell lines (PTE) from Wistar Kyoto (WKY) and spontaneously hypertensive rats (SHR) showed that Slc26a9 is upregulated in SHR PTE cells. Slc26a9 functions as a Cl^-^/HCO~3~^-^ exchanger that mediates part of Cl^-^ and HCO~3~^-^ transport activity in both WKY and SHR cells ([@B44]). Therefore, the exact ion transport mode of Slc26a9 in the kidney is still controversial. **Figure [1](#F1){ref-type="fig"}** depicts the potential ion transport modes of Slc26a9 in different organs.

![Schematic diagram depicting the potential roles of Slc26a9 in different organs. Slc26a9 functions as a Cl^-^ channel in the lung and pancreases. In the stomach and kidney, Slc26a9 can function as both a Cl^-^ channel and Cl^-^/HCO~3~^-^ exchanger. In addition to functioning as a Cl^-^ channel and Cl^-^/HCO~3~^-^ exchanger, four potential roles of Slc26a9 in the duodenum have been discussed in other organs. Slc26a9 and CFTR may interact structurally and/or functionally in a positive fashion to enhance HCO~3~^-^ secretion. Slc26a9 is a crypt enterocyte anion channel that functions indirectly with regard to transepithelial anion transport and is possibly involved in volume control/apoptosis/migration/differentiation.](fphys-09-01197-g001){#F1}

Reciprocal Interaction Between Slc26a9 and CFTR
-----------------------------------------------

Several Slc26a9 regulatory mechanisms, including transcription, protein trafficking, post-translational modifications, macro-molecular complex formation ([@B17]) and WNK regulation ([@B16]; [@B37]; [@B7]), have been described. The reciprocal regulation between CFTR and Slc26a9 has also been extensively discussed ([@B17]; [@B19]; [@B23]) due to the overlapping expression pattern and function of the two proteins in some organs. First, co-immunoprecipitation experiments conducted in HEK293 cells transiently expressing Slc26a9 and CFTR proteins demonstrated the existence of the Slc26a9-CFTR complex ([@B9]). This complex was also confirmed by co-immunoprecipitation in a CF bronchial epithelial cell line (CFBE4Io) stably expressing wild-type or p.phe508del CFTR proteins transduced with Slc26a9 ([@B5]). The direct interaction between the two proteins was further demonstrated by co-immunoprecipitation experiments using the purified Slc26a9 anti-sigma factor antagonist (STAS) domain and purified CFTR R domain ([@B11]). Second, Slc26a9 interacts functionally and/or structurally with CFTR when co-expressed heterologously, but whether this interaction results in enhancement or inhibition is controversial. Some findings suggest that Slc26a9 can enhance CFTR-mediated anion secretion in cultured airway cells and *Xenopus* oocytes ([@B9]; [@B5]; [@B36]), and the reciprocal stimulation of both Slc26a9 and the CFTR current by an STAS-R domain interaction in a protein kinase A (PKA)-dependent fashion has been described. This finding is similar to previous descriptions of the interaction between the anion exchangers Slc26a3 and Slc26a6 ([@B9]). Furthermore, we confirmed that a deletion of Slc26a9 reduces survival in CFTR-deficient mice ([@B26]). Interestingly, Avella et al. also reported that the level of Slc26a9 protein increased in response to co-expression with the CFTR channel ([@B5]). In contrast, Slc26a9 has been found to inhibit (and be inhibited by) CFTR in non-polarized HEK293 cells ([@B36]). Additionally, a recent study showed that Slc26a9 is co-expressed with F508del CFTR, and its trafficking defect led to a PDZ motif-sensitive intracellular retention of Slc26a9 ([@B8]). Therefore, Slc26a9 function and regulation may be highly context-dependent and merit further investigation.

SLC26A9 and Human Diseases
--------------------------

Recent reports have demonstrated that mutations in SLC26A proteins cause a variety of human diseases ([@B17]; [@B18]). In humans, pathogenic mutations in *slc26a9* have been associated with some diseases as well. Initially, based on a public single nucleotide polymorphism (SNP) database, Romero's group found that *slc26a9* polymorphisms cause several functional modifications, including increased or decreased Cl^-^ current and Cl^-^/HCO~3~^-^ exchanger activity and altered protein expression, which could lead to a spectrum of pathophysiologies. However, SLC26A9 is not directly associated with any disease ([@B13]). Nevertheless, a genome-wide pharmacogenomics study investigating neurocognition reported that rs11240594 at *slc26a9* mediates the effects of olanzapine on processing speed, indicating that *slc26a9* may be a novel candidate gene for antipsychotic responses in schizophrenia ([@B31]). This study represents the only report associated with the neural system thus far. In the airways, an analysis of a database of a large European cohort of childhood asthma was performed, resulting in the detection of polymorphisms that carried an increased risk of childhood asthma. Indeed, a polymorphism (at rs2282430) in the *slc26a9* gene was found to be associated with an increased asthma incidence. Additionally, polymorphisms in the 3′ UTR of *slc26a9* that reduce protein expression *in vitro* are associated with asthma. These data provide initial evidence that SLC26A9 may be involved in asthma pathogenesis in humans, suggesting that SLC26A9 may serve as a therapeutic target for allergic airway diseases ([@B4]; [@B30]; [@B42]). Subsequently, a study involving a cohort of 147 patients presenting with diffuse idiopathic bronchiectasis, corresponding to a common lung disease primarily induced in CF patients, was performed. The authors showed that two missense variants (p. Arg575Trp and p.Val486Ile) in the *slc26a9* gene can decrease Cl^-^ channel transport and are related to diffuse idiopathic bronchiectasis, indicating that SLC26A9 is a candidate gene for CF-like disease ([@B6]). Recently, more studies have shown that SNPs in the *slc26a9* gene are associated with CF-related disease onset, suggesting that SLC26A9 is a novel CFTR regulator. Sun and colleagues were the first to report that SNPs (at rs4077468) in the *slc26a9* gene were significantly associated with increases in MI in CF infants ([@B49]). Interestingly, another SNP (rs7512462) in the *slc26a9* gene was pleiotropic for MI, pancreatic insufficiency and early exocrine pancreatic disease in CF individuals ([@B25]; [@B46]; [@B33]; [@B39]) but not progressive lung disease patients ([@B51]; [@B25]; [@B14]). However, new data demonstrated that the rs7512462^∗^C allele is associated with a better response to ivacaftor (VX-770, C24H28N2O3) in patients with CF and mutations, resulting in improvements in pulmonary function ([@B40]). This finding confirmed that Slc26a9 airway modification requires CFTR at the cell surface and that a common variant in Slc26a9 may predict the response to CFTR-directed therapeutics ([@B48]). Furthermore, Blackman's group reported that two SNPs in complete linkage disequilibrium (rs4077468 and rs4077469) located within the slc26a9 gene were found to increase the risk of CFRD onset, but the same genetic alterations in *slc26a9* played a protective role against Type 2 diabetes predisposition ([@B10]; [@B32]). This finding suggests that the ductal fluid flow in the exocrine pancreas was changed due to abnormal chloride channel function resulting from CFTR mutations and that SNPs at the *slc26a9* locus play a substantial role in CFRD, further supporting that Slc26a9 activity might play a role in glucose metabolism ([@B10]). Collectively, these studies suggest that SLC26A9 is a disease modifier and novel therapeutic target that may compensate for impaired CFTR-mediated Cl^-^ secretion. Recently, dysfunction of Slc26a9-mediated ion composition was associated with Sjögren's syndrome (SS) onset ([@B50]), according to the alteration of the expression and cellular localization of Slc26a9 in SS saliva when compared with healthy controls ([@B38]; [@B41]). Although most studies have focused on the role of Slc26a9 in CF-related disease onset, we anticipate that Slc26a9 may also be involved in the pathogenesis of some unreported diseases, such as duodenal ulcers, Type 2 diabetes and hypertension, based on functional analysis ([@B2]; [@B26]; [@B24]). The role of Slc26a9 remains a mystery in many fields and diseases and merits further and intensive investigation. **Table [1](#T1){ref-type="table"}** lists the SNPs in the *slc26a9* gene that are related to different diseases.

###### 

SNPs in the *slc26a9* gene that have been reported to be related to the onset of diseases.

  Disease                                                                              SNPs in the *slc26a9* gene      References
  ------------------------------------------------------------------------------------ ------------------------------- ------------------------------------
  Schizophrenia                                                                        rs11240594                      [@B31]
  Asthma                                                                               rs2282430                       [@B4]
  Meconium ileus                                                                       rs4077468 rs7512462             [@B49] [@B25]
  CF-related diabetes Pancreatic insufficiency and Early exocrine pancreatic disease   rs4077468 rs4077469 rs7512462   [@B10] [@B32] [@B46] [@B25] [@B33]

Summary and Outlook
===================

Slc26a9 is a member of a relatively new Slc26a gene family with multiple functions. Although extensive work has been performed to investigate the expression pattern, functional diversity, regulatory mechanism and pathophysiology of this novel protein in different organs by various systems, the exact physiological and pathophysiological role of Slc26a9 remains a mystery in many fields. Future work should not only further investigate its regulatory role in ion transport but also elucidate the characteristics of its non-ionic transport, i.e., Slc26a9 is possibly involved in volume control/apoptosis/migration/differentiation. Importantly, previous studies mainly focused on the role of Slc26a9 as a disease modifier of CF-related diseases, based on the overlapping expression pattern and function of the two proteins in some organs. However, an increasing number of functional studies have shown that Slc26a9 may also be involved in some non-CF-related diseases, such as Sjögren's syndrome, schizophrenia and unreported diseases, including duodenal ulcers, Type 2 diabetes and hypertension. Therefore, basic and genetic research is required in the future to determine whether Slc26a9 can be a clinically relevant disease modifier or promising therapeutic target.

Author Contributions
====================

XL and TL performed the work and contributed equally. All authors wrote the manuscript.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This work was supported by the National Natural Science Fund of China (81560456 to XL, 81660098 to TL, and 81572438 to BT), the Outstanding Scientific Youth Fund of Guizhou Province (2017-5608 to XL), and the Scientific Innovation Fund of Returned Overseas of Guizhou Province (2016-14 to XL).

[^1]: Edited by: Hongxiang Hui, Southern Medical University, China

[^2]: Reviewed by: Thomas John Brett, Washington University in St. Louis, United States; Jose C. Fernandez-Checa, Consejo Superior de Investigaciones Científicas (CSIC), Spain

[^3]: ^†^These authors have contributed equally to this work and share first authorship

[^4]: This article was submitted to Gastrointestinal Sciences, a section of the journal Frontiers in Physiology
